Several mechanisms for NRF2 activation in cancer have been reported: (1) mutations in KEAP1, CUL3, or NRF2; (2) epigenetic silencing of KEAP1; (3) disruption of interactions between KEAP1 and NRF2 proteins, such as P21 and P62 (41). This evidence concerns the gene CUL3 and cancer.